CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- SC 13G Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure
- SC 13G/A Stake Amended Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 10-K Report Annual Report
- 8-K Event Results of operations
- CORRESP Other Correspondence Between Filers and SEC Staff
- 8-K Event Material agreement · New debt or obligation · Unregistered share sale
- UPLOAD Other SEC-generated Letter
- 8-K Event Executive or director change · Regulation FD disclosure
- 3 Insider Initial Statement of Ownership
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-1/A Offering Registration Statement
- 8-K Event Executive or director change
- UPLOAD Other SEC-generated Letter
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change · Regulation FD disclosure
Page 11 of 14 · 268 filings